1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-7 of 7 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2004Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicityColler, J.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T.
2009Associations between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with TamoxifenSchroth, W.; Goetz, M.; Hamann, U.; Fasching, P.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V.; Ames, M.; Safgren, S.; Kuffel, M.; Ulmer, H.; Bolander, J.; Strick, R.; Beckmann, M.; Koelbl, H.; Weinshilboum, R.; Ingle, J.; Eichelbaum, M.; et al.
2008TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cellsBuck, M.; Coller, J.; Murdter, T.; Eichelbaum, M.; Knabbe, C.
2007Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesSchroth, W.; Antoniadou, L.; Fritz, P.; Schwab, M.; Muerdter, T.; Zanger, U.; Simon, W.; Eichelbaum, M.; Brauch, H.
2010CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratificationSchroth, W.; Hamann, U.; Fasching, P.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H.
2008Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancerBrauch, H.; Schroth, W.; Eichelbaum, M.; Schwab, M.; Harbeck, N.
2009Pharmacogenomics of Tamoxifen TherapyBrauch, H.; Murdter, T.; Eichelbaum, M.; Schwab, M.

Discover